
A multicenter study of 401 patients with invasive aspergillosis found similar 90-day survival with mold-active triazoles and liposomal amphotericin B as primary therapy. As IA risk expands beyond traditional populations, the findings underscore the role of antifungal stewardship and careful treatment selection in infection prevention.






















